© Copyright 2017 Jaguar Health

Jaguar Health, Our Logo, Canalevia And Neonorm Are Our Trademarks That Are Used In This Website. Mytesi Is A Registered Trademark Of Napo Pharmaceuticals, Inc. This Website Also Includes Trademarks, Tradenames And Service Marks That Are The Property Of Other Organizations. Solely For Convenience, Trademarks And Tradenames Referred To In This Website Appear Without The ™ And ® Symbols, But Those References Are Not Intended To Indicate That We Will Not Assert, To The Fullest Extent Under Applicable Law, Our Rights Or That The Applicable Owner Will Not Assert Its Rights, To These Trademarks And Tradenames.


MYTESI® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

Important Safety Information about MYTESI®
MYTESI® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI®.

If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

Click to Read Full Prescribing Information